57 reports

Additionally, increasing research and development (R& D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs.

  • Brain Cancer
  • Cancer
  • Therapy
  • World
  • Market Size

GENE THERAPY IN ONCOLOGY, JUNE 2018, GDHCHT## GLOBALDATA (2018).

  • Brain Cancer
  • China
  • United States
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

Chengdu Research Center of Anti-tumor Gene Therapy has been approved to establish in the company.

  • Brain Cancer
  • China
  • ACON Biotech Co., Ltd
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

Chengdu Research Center of Anti-tumor Gene Therapy has been approved to establish in the company.

  • Brain Cancer
  • China
  • Demand
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd

Innovative immunotherapies and gene therapies look to serve critically unmet needs in the glioblastoma market.

  • Brain Cancer
  • European Union
  • Japan
  • United States
  • Demand

Hoffmann-La Roche Ltd: Annual Revenue, 2011 – 2013 (USD Million) FIG. ## Peregrine Pharmaceuticals, Inc. : Annual Revenue, 2011 – 2013 (USD Million) List of Tables TABLE ## Market Snapshot: Global Glioblastoma Multiforme Treatment Market (2014 and 2022) ## TABLE ## Signatures and Clinical feat

  • Brain Cancer
  • Therapy
  • United States
  • World
  • Market Size
  • Clinical Trial profile. 311 Trial Title
  • Clinical Trial profile. 86 Trial Title

The prominent features of this report are - ##.

  • Brain Cancer
  • Clinical Trial
  • Hospital
  • Therapy
  • Merck & Co., Inc.

Biologics include a broad range of products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.

  • Brain Cancer
  • Arbor Pharmaceuticals, LLC
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Clinical Trial profile. 167 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Brain Cancer
  • Cell Therapy
  • Therapy
  • World
  • Product Initiative

Eighty-one percent (##/ ##) had = ## positive immunogenicity assay.

  • Brain Cancer
  • Immunotherapy
  • United States
  • World
  • Product Initiative
  • FLUCYTOSINE ER + VOCIMAGENE AMIRETROREPVEC - DRUG PROFILE
  • DCVAX-L - DRUG PROFILE

These data indicate that RRV-CD (Toca##)/ ##-FC prodrug activator gene therapy has the potential for application to ovarian cancer.

  • Brain Cancer
  • Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

Eighty-one percent (##/ ##) had = ## positive immunogenicity assay.

  • Brain Cancer
  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Immunovaccine Inc.
  • Anaplastic Astrocytoma - Product Development Milestones
  • Jul 24, 2017: Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma

The presentation is entitled as Regulated Expression of IL-## as Gene Therapy Concomitant with Blockade of PD-## for Treatment of Glioma".

  • Brain Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial profile. 68 Trial Title
  • Clinical Trial profile. 206 Trial Title

The prominent features of this report are - ##.

  • Brain Cancer
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 267 Trial Title

Hoffmann-La Roche Ltd ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## Puma Biotechnology Inc ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ##

  • Brain Cancer
  • Cancer
  • Clinical Trial
  • World
  • Product Initiative
  • Target
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Brain Cancer
  • Clinical Trial
  • Oncology
  • United States
  • World
  • FLUCYTOSINE ER + VOCIMAGENE AMIRETROREPVEC - DRUG PROFILE
  • DCVAX-L - DRUG PROFILE

Tocagen Inc (Tocagen) is a clinical-stage cancer-selective gene therapy company that develops and commercializes product candidates for the treatment of cancer.

  • Brain Cancer
  • Breast Cancer
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.
  • HIGH-GRADE GLIOMA - PIPELINE BY SUMITOMO DAINIPPON PHARMA CO LTD, H2 2017
  • May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings

The presentation is entitled as Regulated Expression of IL-## as Gene Therapy Concomitant with Blockade of PD-## for Treatment of Glioma".

  • Brain Cancer
  • Cancer
  • Hospital
  • Therapy
  • Bristol-Myers Squibb Company
  • M-032 - DRUG PROFILE
  • 110 events, have been reached.

In December 2014, SynerGene Therapeutics, Inc. registered a Phase II trial of combined temozolomide and targeted P## gene therapy (SGT-##) for treatment of patients with recurrent glioblastoma.

  • Brain Cancer
  • Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • MAY 16, 2018: ZIOPHARM ONCOLOGY TO PRESENT DATA FROM CLINICAL STUDIES OF CONTROLLED IL-12 IN BREAST CANCER AND GLIOBLASTOMA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
  • MAY 02, 2018: MEDICENNA AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY OF MDNA55 IN RESPONSE TO STRONG SAFETY DATA AND EARLY EFFICACY READ-OUTS

These results were published in the journal Cancer Gene Therapy.

  • Brain Cancer
  • Cancer
  • Clinical Trial
  • World
  • Product Initiative
  • Official Title
  • Clinical Trial profile. 207 Trial Title

PTAbstract Code: IMMU-## About Ad-RTS-hIL-## plus Veledimex: ZIOPHARM is advancing Ad-RTS-hIL-## plus veledimex as a gene therapy for glioblastoma.

  • Brain Cancer
  • Drug Development
  • Oncology
  • World
  • Product Initiative

Eighty-one percent (##/ ##) had = ## positive immunogenicity assay.

  • Brain Cancer
  • Cancer
  • Therapy
  • United States
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Brain Cancer
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Brain Cancer
  • Targeted Therapy
  • World
  • Product Initiative
  • IMMD

MILLER AND EDITH MILLER CHAIR IN GENE THERAPY, SERVED AS THE PHASE ## TRIAL' S PRINCIPAL INVESTIGATOR.

  • Brain Cancer
  • Infectious Disease
  • Pharmaceutical
  • Vaccine
  • VBI Vaccines Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Hoffmann-La Roche Ltd ## ## ## ## ## ## E.

  • Brain Cancer
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 64 Trial Title
  • Clinical Trial profile. 257 Trial Title

The prominent features of this report are - ##.

  • Brain Cancer
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • FEATURED NEWS & PRESS RELEASES
  • ACCORDANCE WITH THE STUDY S PROTOCOL AND APPLICABLE REGULATIONS. THE COMPANY REPORTED THAT THE STUDY REMAINS OPEN FOR ENROLLMENT.

The presentation is entitled as Regulated Expression of IL-## as Gene Therapy Concomitant with Blockade of PD-## for Treatment of Glioma".

  • Brain Cancer
  • Cancer
  • Hospital
  • Therapy
  • Bristol-Myers Squibb Company
  • Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate

Miller and Edith Miller Chair in Gene Therapy, served as the Phase ## trial' s principal investigator.

  • Brain Cancer
  • Pharmaceutical
  • Vaccine
  • United States
  • VBI Vaccines Inc.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises ## and ## molecules, respectively.

  • Brain Cancer
  • Therapy
  • World
  • Product Initiative
  • IMMD